| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.CMR.0000215035.38436.87 |
| P698 | PubMed publication ID | 16567964 |
| P2093 | author name string | Nancy E Thomas | |
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 97-103 | |
| P577 | publication date | 2006-04-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Melanoma Research | Q6811488 |
| P1476 | title | BRAF somatic mutations in malignant melanoma and melanocytic naevi | |
| P478 | volume | 16 |
| Q90926961 | A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality |
| Q37386014 | A genomic screen identifies TYRO3 as a MITF regulator in melanoma. |
| Q34625205 | A new understanding in the epidemiology of melanoma |
| Q33699419 | Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system |
| Q54441751 | Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients |
| Q45814416 | BRAF and MC1R in melanoma: different in head and neck tumors? |
| Q79787094 | BRAF and NRAS mutations in spitzoid melanocytic lesions |
| Q38114763 | BRAF in Melanoma: Current Strategies and Future Directions |
| Q44966845 | BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter? |
| Q36880772 | Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations |
| Q40129786 | Confirmation of a BRAF mutation-associated gene expression signature in melanoma. |
| Q36970648 | Cutaneous melanoma in genetically modified animals |
| Q33617915 | DNA methylation characteristics of primary melanomas with distinct biological behaviour. |
| Q45269149 | Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. |
| Q36764224 | Epigenetic events in malignant melanoma. |
| Q89659960 | Establishment of a Temperature-Sensitive Model of Oncogene-Induced Senescence in Angiosarcoma Cells |
| Q39312161 | Focus on cutaneous and uveal melanoma specificities. |
| Q37907665 | Gene expression profile of human thyroid cancer in relation to its mutational status |
| Q54524350 | Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma |
| Q38131837 | Implication of ultraviolet light in the etiology of uveal melanoma: A review |
| Q61640129 | In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation |
| Q36632453 | Kinase inhibitors for cardiovascular disease |
| Q44036972 | Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma |
| Q40157058 | Loss of maspin expression contributes to a more invasive potential in malignant melanoma |
| Q38131383 | MEK inhibition in the treatment of advanced melanoma |
| Q46382784 | Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma |
| Q34215658 | Molecular Alternations in Uveal Melanoma |
| Q38093446 | Molecular and cellular pathogenesis of melanoma initiation and progression. |
| Q46988780 | Molecular heterogeneity of malignant melanomas |
| Q26795735 | Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets |
| Q43188626 | Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure |
| Q27852445 | NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. |
| Q36817127 | New approaches in metastatic melanoma: biological and molecular targeted therapies |
| Q38065194 | New therapeutic options in systemic treatment of advanced cutaneous melanoma |
| Q58024781 | Oncogenic B-RAFV600E Promotes Anchorage-Independent Survival of Human Melanocytes |
| Q35941204 | Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern |
| Q35911350 | Personalized therapy in endometrial cancer: Challenges and opportunities |
| Q43841667 | Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma |
| Q36002845 | Raf kinases: function, regulation and role in human cancer |
| Q38367168 | Renal effects of targeted anticancer therapies |
| Q37141819 | Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. |
| Q24594566 | TWIST1 Is an ERK1/2 Effector That Promotes Invasion and Regulates MMP-1 Expression in Human Melanoma Cells |
| Q37817713 | Targeting BRAF for patients with melanoma. |
| Q37752347 | Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges. |
| Q84080830 | The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo |
| Q54633643 | The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. |
| Q37925630 | The photobiology of melanocytes modulates the impact of UVA on sunlight-induced melanoma |
| Q37951743 | Towards new therapeutic approaches for malignant melanoma |
| Q38118851 | Vemurafenib and ipilimumab: New agents for metastatic melanoma |
Search more.